Cargando…

Platelet Activation in High D-Dimer Plasma Plays a Role in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Mutant Lung Adenocarcinoma

OBJECTIVE: Platelet activation and adhesion to cancer cells increase the release of multiple factors that contribute to EMT and chemoresistance. Elevated levels of D-dimer have been associated with poor clinical outcomes in lung cancer. Platelets in high D-dimer plasma may be activated and implicate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Meng-Jung, Weng, Chih-Ming, Chao, Wei, Fang, Yueh-Fu, Chung, Fu-Tsai, Lin, Chien-Huang, Kuo, Han-Pin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214222/ https://www.ncbi.nlm.nih.gov/pubmed/35756605 http://dx.doi.org/10.3389/fonc.2022.876051

Ejemplares similares

Lymphocyte percentage and platelet count correlate with the treatment outcome to tyrosine kinase inhibitors in epidermal growth factor receptor–mutated lung adenocarcinoma
por: Li, Chi-Cheng, et al.
Publicado: (2020)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
por: Wu, Shang-Gin, et al.
Publicado: (2016)

Transformation From Adenocarcinoma to Pleomorphic Carcinoma as an Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Nishimatsu, Kanako, et al.
Publicado: (2021)

T790M and Acquired Resistance of Epidermal Growth Factor Receptor to Tyrosine Kinase Inhibitors in Patients with Lung Adenocarcinoma
por: Mirtavoos-Mahyari, Hanifeh, et al.
Publicado: (2022)

Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients
por: Chang, John Wen‐Cheng, et al.
Publicado: (2022)

Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma
por: Chen, Ying-Yi, et al.
Publicado: (2023)

A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
por: Han, Ji-Youn, et al.
Publicado: (2017)

First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
por: Huang, Allen Chung-Cheng, et al.
Publicado: (2021)

Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions
por: Hsu, Ping-Chih, et al.
Publicado: (2016)

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan
por: Chang, John Wen‐Cheng, et al.
Publicado: (2022)

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Chang, Youjin, et al.
Publicado: (2013)

The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
por: Huang, Yen-Hsiang, et al.
Publicado: (2018)

Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes
por: Kuo, Chia-Yu, et al.
Publicado: (2022)

Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
por: Tsai, Ming-Ju, et al.
Publicado: (2018)

Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2015)

Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2016)

Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors
por: Chen, Justin A., et al.
Publicado: (2020)

A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
por: Miyoshi, Seigo, et al.
Publicado: (2015)

Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2015)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
por: Chen, Chieh-Lung, et al.
Publicado: (2023)

Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors
por: Liao, Bin-Chi, et al.
Publicado: (2016)

Suppression of tumor immune microenvironment via microRNA‐1 after epidermal growth factor receptor‐tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma
por: Kawana, Sachiko, et al.
Publicado: (2020)

Estrogen Receptor β1 Expression Patterns Have Different Effects on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors’ Treatment Response in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma
por: Zhang, Lijuan, et al.
Publicado: (2021)

Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor
por: Xie, Yalin, et al.
Publicado: (2021)

A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition
por: Zhang, Nana, et al.
Publicado: (2017)

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma
por: Wu, Chiao-En, et al.
Publicado: (2022)

Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2016)

Mechanisms of Activation of Receptor Tyrosine Kinases: Monomers or Dimers
por: Maruyama, Ichiro N.
Publicado: (2014)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
por: Chung, Fu-Tsai, et al.
Publicado: (2015)

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
por: Wang, Sheng‐Yuan, et al.
Publicado: (2021)

Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer
por: Valley, Christopher C., et al.
Publicado: (2015)

E-cadherin expression in the tumor microenvironment of advanced epidermal growth factor receptor-mutant lung adenocarcinoma and the association with prognosis
por: Chang, Yu-Ping, et al.
Publicado: (2023)

Gastric metastasis and transformation of primary lung adenocarcinoma to small cell cancer after acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors: A case report
por: Liu, Jing, et al.
Publicado: (2021)

Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor
por: Watanabe, Kousuke, et al.
Publicado: (2018)

Syndecan 4-c-ros oncogene 1 fusion as a mechanism of acquired resistance in epidermal growth factor receptor mutant lung adenocarcinoma
por: Zhu, You-Cai, et al.
Publicado: (2019)

Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung Adenocarcinoma
por: Yamauchi, Mai, et al.
Publicado: (2012)

Subsequent treatment of epidermal growth factor receptor-tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma
por: Qiao, Xiaojuan, et al.
Publicado: (2015)

Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
por: Chang, Yoon Soo, et al.
Publicado: (2016)

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
por: Park, Sojung, et al.
Publicado: (2021)

Epidermal growth factor receptor T790M mutation as a prognostic factor in EGFR-mutant non-small cell lung cancer patients that acquired resistance to EGFR tyrosine kinase inhibitors
por: Ma, Guangzhi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_362e3uf72l4d1i2cbb2ucbivkp